ALKERMES, INC. for ALKERMES, INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Patient access and maintain six protected classes for bipolar disorders and schizophrenia under Medicare Part D; Policies regarding drug pricing and Most Favored Nations proposals; Medicaid statutory rebate increases;
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILLIAM PATRICK HIBBS | — |
| ZACHARY MICHAEL MARSHALL | — |
| PETER NORMAN | — |
Health Issues HCR
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 55509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R. 7148 - Consolidated Appropriations Act, 2026; H.R. 1 - One Big Beautiful Bill Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILLIAM PATRICK HIBBS | — |
| ZACHARY MICHAEL MARSHALL | — |
| PETER NORMAN | — |
Alcohol and Drug Abuse ALC
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILLIAM PATRICK HIBBS | — |
| ZACHARY MICHAEL MARSHALL | — |
| PETER NORMAN | — |
Tariff (miscellaneous tariff bills) TAR
Policies impacting pharmaceutical distribution and manufacturing
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILLIAM PATRICK HIBBS | — |
| ZACHARY MICHAEL MARSHALL | — |
| PETER NORMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.